NCT Number: NCT03760120
Short-term Effects of Physiotherapy on LCI
Although some studies have brought some evidences about the efficacy of positive expiratory pressure (PEP)-mask therapy as an airway clearance technique, yet it is not clearly understood what is the contribution of this technique in modifying peripheral ventilation inhomogeneity, a typical feature of patients with Cystic Fibrosis (CF).
The aim of this study is to investigate how PEP-MASK affects ventilation inhomogeneity in children and adolescents, with moderate to normal CF lung disease by the change in acinar airways (Sacin), lung clearance index (LCI) and conductive airways (Scond) indexes derived from nitrogen multiple-breath washout test (N2MBW).
Looking for future studies?
Notify MeKey information
Conditions
Age range
5 year–18 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Azienda Ospedaliero-Universitaria Meyer, Florence, Italy
About this study
Investigational device: PEP-MASK=Positive Expiratory Pressure delivered through a face mask.
Standard Operating Procedures used for evaluating CF lung disease and ventilation inhomogeneity.
Sample size: Based on preliminary data collected on seven subjects who performed nitrogen multiple-breath washout test before and after PEP-MASK, assuming a variation of 20% of Sacin, the study requires a sample size of 18 subjects.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- CF diagnosis
- Patients hospitalized for a scheduled intravenous antibiotics cycle and regularly followed-up by the CF Centre
- ≥ 15 kilograms
- FEV1 ≥ 40%predicted
- Ability to perform NMBW test
- Ability to perform spirometry
- Willing to adhere to protocol procedures
- Patients in treatment with PEP-MASK
Exclusion criteria
- Pulmonary Exacerbation within two last week
- Burkholderia cepacia infection
- Patients in lung transplantation waiting list
- Patients undergoing non invasive mechanical ventilation or oxygen therapy
Treatment and study plan
Primary outcomes
-
Effect of PEP-MASK on ventilation heterogeneity (Sacin)
Time frame: Right after intervention/sham procedure
Acinar airways (Sacin) mean difference between treatments
Secondary outcomes
-
Effect of PEP-MASK on ventilation heterogeneity (Scond)
Time frame: Right after intervention/sham procedure
Conductive airways (Scond) mean difference between treatments
-
Effect of PEP-MASK on ventilation heterogeneity (LCI)
Time frame: Right after intervention/sham procedure
Ventilation heterogeneity (LCI) mean difference between treatments
-
Sputum weight
Time frame: From the beginning to the end of each intervention/sham procedure
Sputum weight (grams) will be collected throughout the active or sham interventions
-
Oxygen saturation
Time frame: From the beginning to the end of each intervention/sham procedure
Oxygen saturation (SpO2) will be monitored throughout the active or sham interventions
Sponsors and collaborators
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Other
Registry information
Official study title
Short-term Effects of Positive Expiratory Pressure Mask on Ventilation Inhomogeneity in Children and Adolescents With Cystic Fibrosis
Acronym: SPICy
Important dates
- Study start
- 2016
- Primary completion
- 2022
- Study completion
- 2022
- First posted
- Nov 30, 2018
- Registry last updated
- Dec 29, 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Trikafta in Cystic Fibrosis Patients
NCT03506061
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Birmingham, Alabama, United States
View Trial DetailsEvaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
NCT06154447
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Hollywood, Florida, United States
View Trial DetailsImpact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory Study
NCT02715921
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Irvine, California, United States
View Trial DetailsHERO-2: Home-Reported Outcomes With CFTR Modulator Therapy
NCT04798014
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Indianapolis, Indiana, United States
View Trial Details